肾康注射液对顺铂诱导小鼠急性肾损伤的治疗作用及机制
该研究建立顺铂诱导的急性肾损伤小鼠模型,观察肾康注射液的疗效并探讨机制。结果显示肾康注射液改善肾功能、减轻炎症与氧化应激,LC-MS/MS检出4种成分入肾,网络药理学提示PI3K/AKT、TNF、MAPK和p53通路参与。
要点
- 肾康注射液可降低顺铂致AKI小鼠的SCr、BUN和尿蛋白水平。
- 肾康注射液抑制IL-34、IL-6、TNF-α,上调SOD、GSH,下调MDA。
- 机制可能涉及PI3K/AKT、TNF、MAPK和p53信号通路。
核心结论
- 肾康注射液通过抗氧化和抗炎作用减轻顺铂诱导的肾毒性,机制与调节PI3K/AKT、MAPK、TNF和p53信号通路有关。
研究设计与样本
- 研究建立顺铂诱导的急性肾损伤小鼠模型,采用生化指标检测肾功能、HE染色观察肾组织病理,LC-MS/MS评估肾康注射液成分在肾脏的分布,并检测炎症因子与氧化应激指标,结合网络药理学阐明机制。
主要发现
- 顺铂诱导小鼠肾脏过度炎症和严重损伤,肾康注射液显著改善肾损伤和肾功能。
- 肾康注射液降低肾功能标志物SCr、BUN和尿蛋白水平,抑制炎症因子IL-34、IL-6和TNF-α产生。
- 肾康注射液上调抗氧化剂SOD和GSH、下调氧化剂MDA以修复氧化平衡。
- LC-MS/MS在肾脏中检出肾康注射液的4种成分。
- 网络药理学提示PI3K/AKT、TNF、MAPK和p53是肾康注射液对抗顺铂诱导AKI的可能信号通路,与炎症、氧化应激和凋亡相关。
临床怎么用
- 该研究为肾康注射液用于顺铂相关急性肾损伤的临床适应症提供了科学依据,但需结合临床进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Shenkang injection (SKI), a Chinese patent medicine injection, has been approved for the treatment of chronic kidney disease (CKD) due to its definite clinical therapeutic efficacy. However, the effect and associated underlying mechanism of Shenkang injection against cisplatin (CDDP)-induced acute kidney injury (AKI) has not yet been well elucidated. AIM OF THE STUDY: This study aims to investigate the therapeutic effect and associated underlying mechanism of Shenkang injection against CDDP-induced AKI. MATERIALS AND METHODS: We established a CDDP-induced AKI mouse model to evaluate renal function by biochemical markers measurement and to observe histopathological alterations by haemotoxylin and eosin (HE)-staining sections of renal. In addition, the distribution of representative components of SKI in the kidneys of mice was evaluated by liquid chromatography tandem mass spectrometry (LC-MS/MS). Furthermore, the degree of oxidative stress and inflammation were assessed by detecting the levels of inflammatory cytokines and oxidants, while the related mechanisms were elucidated by network pharmacology. RESULTS: CDDP could induce excessive inflammation and severe injury to the kidneys of mice. However, SKI significantly ameliorated the kidney damages and improved the renal function by reducing the levels of renal function markers (SCr, BUN and urine protein), and inhibiting the production of inflammatory cytokines IL-34, IL-6 and TNF-α. SKI repaired oxidative balance through up-regulation of antioxidants SOD and GSH and down-regulated oxidants MDA. Moreover, 4 components from SKI were detected in the kidney by LC-MS/MS quantification. In addition, pharmacology network indicated the PI3K/AKT, TNF, MAPK, and p53 were the possible signaling pathways for the therapeutic effect of SKI against CDDP-induced AKI, which were related to inflammation, oxidative stress and apoptosis. CONCLUSION: In the present study, we for the first time demonstrated that SKI alleviates CDDP-induced nephrotoxicity by antioxidant and anti-inflammation via regulating PI3K/AKT, MAPK, TNF, and p53 signaling pathways. The study may provide a scientific rationale for the clinical indication of SKI.
引用
- Su J, He T, You J, et al. Therapeutic effect and underlying mechanism of Shenkang injection against cisplatin-induced acute kidney injury in mice. J Ethnopharmacol. 2022. PMID: 36216195. doi:10.1016/j.jep.2022.115805
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。